AKT1 and cancer: The observed significant decrease in the presence of cpd29 + cholesterol + lovastatin compared to the cpd29 alone could possibly be due to the impact of lovastatin on other pathways, including inhibition of protein kinase B (AKT)/mammalian target of rapamycin (mTOR) [34,35] in cancer cells.